logo

Larimar Therapeutics, Inc. (LRMR)



Trade LRMR now with
  Date
  Headline
3/25/2022 7:28:51 AM Larimar Therapeutics Q4 Net Loss $9.1 Mln Or $0.50/Shr Vs Loss Of $14.2 Mln Or $0.89/Shr Last Year
2/15/2022 4:56:32 PM William Blair Lowers Larimar Therapeutics, Inc. (LRMR) To Market Perform From Outperform
8/12/2019 7:52:50 AM Wedbush Is Cutting Zafgen, Inc (ZFGN) FY20 Estimate To -0.96 From -0.88
8/12/2019 7:52:36 AM Wedbush Is Cutting Zafgen, Inc (ZFGN) Q4 20 Estimate To -0.24 From -0.22
8/12/2019 7:51:54 AM Wedbush Is Lowering Zafgen, Inc (ZFGN) Q3 20 Estimate To -0.25 From -0.23
8/12/2019 7:51:34 AM Wedbush Is Lowering Zafgen, Inc (ZFGN) Q2 20 Estimate To -0.24 From -0.22
8/12/2019 7:51:23 AM Wedbush Is Lowering Zafgen, Inc (ZFGN) Q1 20 Estimate To -0.24 From -0.22
8/12/2019 7:51:00 AM Wedbush Is Lowering Zafgen, Inc (ZFGN) FY19 Estimate To -1.22 From -1.12
8/12/2019 7:50:46 AM Wedbush Is Cutting Zafgen, Inc (ZFGN) Q4 19 Estimate To -0.26 From -0.23
8/12/2019 7:50:27 AM Wedbush Is Lowering Zafgen, Inc (ZFGN) Q3 19 Estimate To -0.29 From -0.25
8/12/2019 7:49:35 AM Wedbush Reiterates Zafgen, Inc (ZFGN) At Outperform With $6 Price Target
8/8/2018 8:54:47 AM Wedbush Is Increasing Zafgen, Inc (ZFGN) FY19 Estimate To -1.82 From -1.97
8/8/2018 8:54:30 AM Wedbush Is Increasing Zafgen, Inc (ZFGN) FY18 Estimate To -1.99 From -2.09
8/8/2018 8:54:17 AM Wedbush Is Raising Zafgen, Inc (ZFGN) Q3 18 Estimate To -0.43 From -0.47